Real-world experience of larotrectinib in children, adolescents and young adults with TRK fusion solid tumors: The SACHA-France experience

Leukemia

Characteristics and outcome determinants in children, adolescents and young adults who failed tisagenlecleucel for B-cell acute lymphoblastic leukemia

Leukemia

Lecornec N, Rabian F, Dourthe ME, Chevillon F, Yakouben K, Chaillou D, Caillat-Zucman S, Cuffel A, Lesprit E, Arnould A, Naudin J, Roupret-Serzec J, Parquet N, Brignier A, Guérin-El Khourouj V, Lainey E, Caye-Eude A, Arfeuille C, Clappier E, Kim R, Mathis S, Chaix ML, Azoulay E, Dalle JH, Madelaine I, Larghero J, Baruchel A, Boissel N

doi: 10.1038/s41375-026-02867-9

Lymphoma

Improvements over time in survival after post-transplant relapse of adult T-cell leukaemia/lymphoma and trends of salvage therapy in a real-world experience

Br J Haematol

Itonaga H, Fukushima T, Kato K, Muranushi H, Tokunaga M, Miyazono T, Ito A, Eto T, Suehiro Y, Kato T, Fujioka M, Kawakita T, Uchida N, Mori Y, Yoshimitsu M, Nakamae H, Morichika K, Ishitsuka K, Kanda J, Fukuda T, Atsuta Y, Fuji S, ATL working groups of the Japanese Society for Transplantation and Cellular Therapy

doi: 10.1111/bjh.70631

Sarcoma

Outcome of metastatic non-rhabdomyosarcoma soft tissue sarcoma in children and young adults treated on children's oncology group ARST0332 trial

J Natl Cancer Inst

Oberoi S, Gao Z, Xue W, Randall RL, Coffin CM, Million L, Wolden S, McCarville MB, Kao SC, Venkatramani R, Spunt SL, Weiss AR

doi: 10.1093/jnci/djag211

Further Publications

Real-world immunotherapy outcomes in unresectable peritoneal mesothelioma: A French experience

Eur J Cancer

Smolenschi C, Boileve A, Vaflard P, Watson S, Sourouille I, Valery M, Hollebecque A, Lion M, Anglaret S, Camilleri G, Gelli M, Diebakate L, Megherbi A, Tarabay A, Benhaim L, Fernandez-De-Sevilla E, Pudlarz T, Fuerea AC, Ducreux M, Boige V

doi: 10.1016/j.ejca.2025.116066

Leukemia

Real-world effectiveness and safety of acalabrutinib in chronic lymphocytic leukaemia: Multicentre experience

Br J Haematol

Duminuco A, Leotta D, Allegra A, Caracciolo D, Caruso L, Chiarenza A, Del Fabro V, Di Martina V, Figuera A, Fiumara PF, Gentile M, Innao V, Mancuso S, Martino EA, Mosca A, Motta G, Pedalino F, Rossi M, Stagno F, Tona G, Di Raimondo F, Palumbo GA

doi: 10.1111/bjh.70638

Central Nervous System Tumors

Survival of European adolescents and young adults diagnosed with central nervous system tumours and comparison with younger and older age groups: EUROCARE-6 results

Eur J Cancer

McCabe M, Rossi S, Cerza F, Massimino M, Gianno F, Spycher BD, Marcos-Gragera R, Bennett D, Lasalvia P, Didonè F, El Karoui NJ, Ragusa R, Mayer-da-Silva A, Mousavi SM, Trama A, EUROCARE-6 WG

doi: 10.1016/j.ejca.2025.115661

Lymphoma

Brentuximab-vedotin and bendamustine for relapsed or refractory Hodgkin lymphoma: the LYSA real-world experience

Haematologica

Basile G, Neuville A, Martineau D, Delapierre B, Dubois S, Noel R, Durot E, Caillet A, Labouré G, Laribi K, Gros FX, Bernard S, Mineur A, Borel C, Chartier L, Damaj G, Bouabdallah K, Galtier J

doi: 10.3324/haematol.2025.300289

Multiple Myeloma (MM)

Real-World Evaluation of Talquetamab for the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM): An International Myeloma Working Group Immunotherapy Registry Real-World Analysis

Am J Hematol

Janakiram M, Tan CR, Mian H, Huang CY, Popat R, Martínez-Lopez J, Kastritis E, Chng WJ, Kapoor P, Dave M, Bal S, Garderet L, Corraes AMS, Riedhammer C, Steinbrunn T, Corona M, Nagarajan C, Einsele H, Martin T, Krishnan A, Lin Y

doi: 10.1002/ajh.70376

Non-Malignant Blood Disorders

Real-world efficacy and safety of fostamatinib in ITP patients: Italian multicentre experience. GIMEMA ITP1122 study

Br J Haematol

Lucchini E, Vianelli N, Consoli U, Carli G, Carrai V, Carpenedo M, De Stefano V, Gaidano G, Palandri F, Auteri G, Rossi E, Patriarca A, Innao V, Marchesini G, Ballerini M, Rossetti MC, Mosini G, Sciancalepore P, Agnelli Giacchello J, Musto P, Rivolti E, Soverini G, Borchiellini A, Clissa C, Pane F, Galimberti S, Pavone V, Poloni A, Buccisano F, Musso M, Fazi P, Paoloni F, Gorreo Renzulli L, Zaja F

doi: 10.1111/bjh.70069

Related content

Characteristics and outcome determinants in children, adolescents and young adults who failed tisagenlecleucel for B-cell acute lymphoblastic leukemia

Improvements over time in survival after post-transplant relapse of adult T-cell leukaemia/lymphoma and trends of salvage therapy in a real-world experience

Outcome of metastatic non-rhabdomyosarcoma soft tissue sarcoma in children and young adults treated on children's oncology group ARST0332 trial

Real-world immunotherapy outcomes in unresectable peritoneal mesothelioma: A French experience

Real-world effectiveness and safety of acalabrutinib in chronic lymphocytic leukaemia: Multicentre experience

Survival of European adolescents and young adults diagnosed with central nervous system tumours and comparison with younger and older age groups: EUROCARE-6 results

Brentuximab-vedotin and bendamustine for relapsed or refractory Hodgkin lymphoma: the LYSA real-world experience

Real-World Evaluation of Talquetamab for the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM): An International Myeloma Working Group Immunotherapy Registry Real-World Analysis

Real-world efficacy and safety of fostamatinib in ITP patients: Italian multicentre experience. GIMEMA ITP1122 study